JP2021522291A5 - - Google Patents

Info

Publication number
JP2021522291A5
JP2021522291A5 JP2020560750A JP2020560750A JP2021522291A5 JP 2021522291 A5 JP2021522291 A5 JP 2021522291A5 JP 2020560750 A JP2020560750 A JP 2020560750A JP 2020560750 A JP2020560750 A JP 2020560750A JP 2021522291 A5 JP2021522291 A5 JP 2021522291A5
Authority
JP
Japan
Prior art keywords
formula
pharmaceutically acceptable
acceptable salt
compound
cognitive impairment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020560750A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021522291A (ja
JP7314173B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2019/059390 external-priority patent/WO2019211081A1/en
Publication of JP2021522291A publication Critical patent/JP2021522291A/ja
Publication of JP2021522291A5 publication Critical patent/JP2021522291A5/ja
Priority to JP2023113932A priority Critical patent/JP2023130467A/ja
Application granted granted Critical
Publication of JP7314173B2 publication Critical patent/JP7314173B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020560750A 2018-04-30 2019-04-12 認知障害の治療のためのｓＧＣ活性化薬及びｓＧＣ刺激薬の使用 Active JP7314173B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023113932A JP2023130467A (ja) 2018-04-30 2023-07-11 認知障害の治療のためのｓＧＣ活性化薬及びｓＧＣ刺激薬の使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP18170049.3 2018-04-30
EP18170049 2018-04-30
PCT/EP2019/059390 WO2019211081A1 (en) 2018-04-30 2019-04-12 The use of sgc activators and sgc stimulators for the treatment of cognitive impairment

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023113932A Division JP2023130467A (ja) 2018-04-30 2023-07-11 認知障害の治療のためのｓＧＣ活性化薬及びｓＧＣ刺激薬の使用

Publications (3)

Publication Number Publication Date
JP2021522291A JP2021522291A (ja) 2021-08-30
JP2021522291A5 true JP2021522291A5 (enExample) 2022-04-04
JP7314173B2 JP7314173B2 (ja) 2023-07-25

Family

ID=62091739

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020560750A Active JP7314173B2 (ja) 2018-04-30 2019-04-12 認知障害の治療のためのｓＧＣ活性化薬及びｓＧＣ刺激薬の使用
JP2023113932A Pending JP2023130467A (ja) 2018-04-30 2023-07-11 認知障害の治療のためのｓＧＣ活性化薬及びｓＧＣ刺激薬の使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023113932A Pending JP2023130467A (ja) 2018-04-30 2023-07-11 認知障害の治療のためのｓＧＣ活性化薬及びｓＧＣ刺激薬の使用

Country Status (6)

Country Link
US (1) US20210052528A1 (enExample)
EP (1) EP3787610A1 (enExample)
JP (2) JP7314173B2 (enExample)
CN (1) CN112055584A (enExample)
CA (1) CA3098475A1 (enExample)
WO (1) WO2019211081A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109890379A (zh) 2016-10-11 2019-06-14 拜耳制药股份公司 包含sGC活化剂和盐皮质激素受体拮抗剂的组合产品
EP3525779B1 (de) 2016-10-11 2024-06-05 Bayer Pharma Aktiengesellschaft Kombination enthaltend den sgc stimulator vericuguat und den mineralcorticoid-rezeptor-antagonist finerenone
WO2020245342A1 (en) * 2019-06-07 2020-12-10 Bayer Aktiengesellschaft The use of sgc activators for the treatment of ophthalmologic diseases
AU2021398486A1 (en) * 2020-12-10 2023-06-22 Bayer Aktiengesellschaft The use of sgc activators for the treatment of ophthalmologic diseases
EP4326268A1 (en) * 2021-04-20 2024-02-28 Tisento Therapeutics Inc. Treatment of cns diseases with sgc stimulators
CN117337278A (zh) * 2021-05-14 2024-01-02 南京明德新药研发有限公司 烷基羧酸化合物及其应用
EP4233851A1 (en) * 2022-02-25 2023-08-30 Charité - Universitätsmedizin Berlin A soluble guanylat cyclase activator for treating chronic vascular dysfunction
EP4472620A1 (en) * 2022-02-01 2024-12-11 Charité - Universitätsmedizin Berlin A soluble guanylat cyclase activator for treating chronic vascular dysfunction
CN120225200A (zh) * 2022-06-24 2025-06-27 阿丽派欧株式会社 用于预防和治疗神经退行性疾病的组合物和方法

Family Cites Families (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ302691B6 (cs) 1998-07-08 2011-09-07 Sanofi - Aventis Deutschland GmbH N-Arylamidová sloucenina, zpusob její prípravy, farmaceutický prostredek tuto slouceninu obsahující, tato sloucenina pro použití jako aktivátor a pro použití k terapii nebo profylaxi
DE19943636A1 (de) 1999-09-13 2001-03-15 Bayer Ag Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE19943634A1 (de) 1999-09-13 2001-04-12 Bayer Ag Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE19943635A1 (de) 1999-09-13 2001-03-15 Bayer Ag Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE10109859A1 (de) 2001-03-01 2002-09-05 Bayer Ag Neuartige Aminodicarbonsäurederivate
DE10109858A1 (de) 2001-03-01 2002-09-05 Bayer Ag Neuartige halogensubstituierte Aminodicarbonsäurederivate
DE10110750A1 (de) 2001-03-07 2002-09-12 Bayer Ag Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE10110749A1 (de) 2001-03-07 2002-09-12 Bayer Ag Substituierte Aminodicarbonsäurederivate
DE10220570A1 (de) 2002-05-08 2003-11-20 Bayer Ag Carbamat-substituierte Pyrazolopyridine
IL150509A (en) * 2002-07-01 2007-07-04 Joseph Kaspi Pharmaceutical preparations containing donafazil hydrochloride
DE102005050498A1 (de) 2005-10-21 2007-06-06 Bayer Healthcare Aktiengesellschaft Cyclopropylessigsäure-Derivate und ihre Verwendung
DE102005050377A1 (de) 2005-10-21 2007-04-26 Bayer Healthcare Ag Heterocyclische Verbindungen und ihre Verwendung
DE102005050376A1 (de) 2005-10-21 2007-05-31 Bayer Healthcare Ag Dicarbonsäure-Derivate und ihre Verwendung
DE102005050497A1 (de) 2005-10-21 2007-04-26 Bayer Healthcare Ag Difluorphenol-Derivate und ihre Verwendung
DE102005050375A1 (de) 2005-10-21 2007-04-26 Bayer Healthcare Ag Tetrazol-Derivate und ihre Verwendung
DE102007015035A1 (de) 2007-03-29 2008-10-02 Bayer Healthcare Ag Substituierte Dibenzoesäure-Derivate und ihre Verwendung
DE102007015034A1 (de) 2007-03-29 2008-10-02 Bayer Healthcare Ag Lactam-substituierte Dicarbonsäuren und ihre Verwendung
BRPI0816382A2 (pt) 2007-09-06 2015-02-24 Merck Sharp & Dohme Composto, composição, e, métodos para ativar a guanilato ciclase solúvel e para tratar ou previnir doenças
WO2009068652A1 (en) 2007-11-30 2009-06-04 Smithkline Beecham Corporation 2, 6-disubstituted pyridines and 2, 4-disubstituted pyrimidines as soluble guanylate cyclase activators
TW200938529A (en) 2007-12-03 2009-09-16 Smithkline Beecham Corp Compounds
CA2720343A1 (en) 2008-04-04 2009-10-08 Takeda Pharmaceutical Company Limited Heterocyclic derivative and use thereof
DE102008018675A1 (de) 2008-04-14 2009-10-15 Bayer Schering Pharma Aktiengesellschaft Oxo-heterocyclisch substituierte Carbonsäure-Derivate und ihre Verwendung
WO2010015653A1 (en) 2008-08-07 2010-02-11 Smithkline Beecham Corporation Pyrimidine derivatives as activators of soluble guanylate cyclase
WO2010015652A2 (en) 2008-08-07 2010-02-11 Smithkline Beecham Corporation Thiazole compounds as activators of soluble guanylate cyclase
AU2009322836B2 (en) 2008-11-25 2013-04-04 Merck Sharp & Dohme Corp. Soluble guanylate cyclase activators
TW201028152A (en) 2009-01-20 2010-08-01 Merck & Co Inc Soluble guanylate cyclase activators
KR20110133034A (ko) 2009-02-26 2011-12-09 머크 샤프 앤드 돔 코포레이션 가용성 구아닐레이트 시클라제 활성화제
DE102009012314A1 (de) 2009-03-09 2010-09-16 Bayer Schering Pharma Aktiengesellschaft Oxo-heterocyclisch substituierte Alkylcarbonsäuren und ihre Verwendung
CN101670106A (zh) 2009-09-22 2010-03-17 吉林大学 可溶性鸟苷酸环化酶的天然激活剂
WO2011056511A2 (en) 2009-10-26 2011-05-12 Auspex Pharmaceuticals, Inc. 4,6-diaminopyrimidine stimulators of soluble guanylate cyclase
DE102009046115A1 (de) 2009-10-28 2011-09-08 Bayer Schering Pharma Aktiengesellschaft Substituierte 3-Phenylpropansäuren und ihre Verwendung
WO2011115804A1 (en) 2010-03-17 2011-09-22 Ironwood Pharmaceuticals, Inc. Sgc stimulators
US9284301B2 (en) 2010-03-25 2016-03-15 Merck Sharp & Dohme Corp. Soluble guanylate cyclase activators
DE102010020553A1 (de) 2010-05-14 2011-11-17 Bayer Schering Pharma Aktiengesellschaft Substituierte 8-Alkoxy-2-aminotetralin-Derivate und ihre Verwendung
DE102010021637A1 (de) 2010-05-26 2011-12-01 Bayer Schering Pharma Aktiengesellschaft Substituierte 5-Fluor-1H-Pyrazolopyridine und ihre Verwendung
KR20140019004A (ko) 2010-05-27 2014-02-13 머크 샤프 앤드 돔 코포레이션 가용성 구아닐레이트 시클라제 활성화제
EP2588465B1 (en) 2010-06-30 2017-01-25 Ironwood Pharmaceuticals, Inc. Sgc stimulators
EP2632551B1 (en) 2010-10-28 2016-07-06 Merck Sharp & Dohme Corp. Soluble guanylate cyclase activators
CN107266433A (zh) 2010-11-09 2017-10-20 铁木医药有限公司 sGC刺激剂
PH12013501143A1 (en) 2010-12-07 2013-07-08 Bayer Ip Gmbh Substituted 1-benzylcycloalkylcarboxlic acids and use thereof
JP5715713B2 (ja) 2011-03-10 2015-05-13 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 可溶性グアニル酸シクラーゼ活性化因子
DE102011007272A1 (de) * 2011-04-13 2012-10-18 Bayer Pharma Aktiengesellschaft Verzweigte 3-Phenylpropionsäure-Derivate und ihre Verwendung
AR086589A1 (es) 2011-05-30 2014-01-08 Astellas Pharma Inc Compuestos imidazopiridina
US8815857B2 (en) 2011-08-12 2014-08-26 Boehringer Ingelheim International Gmbh Soluble guanylate cyclase activators
CN106117194A (zh) 2011-12-27 2016-11-16 铁木医药有限公司 可用作sgc刺激剂的2‑苄基、3‑(嘧啶‑2‑基)取代的吡唑类
KR20140144696A (ko) 2012-04-16 2014-12-19 도아 에이요 가부시키가이샤 ２환성 화합물
DE102012208530A1 (de) 2012-05-22 2013-11-28 Bayer Pharma AG Substituierte Piperidinoacetamide und ihre Verwendung
RS55651B1 (sr) 2012-07-20 2017-06-30 Bayer Pharma AG Nove 5-aminotetrahidrohinolin-2-karbonske kiseline i njihova upotreba
CA2879456A1 (en) 2012-07-20 2014-01-23 Bayer Pharma Aktiengesellschaft Substituted aminoindane- and aminotetralincarboxylic acids and use thereof
HRP20191755T1 (hr) 2012-09-07 2019-12-27 Boehringer Ingelheim International Gmbh Alkoksipirazoli kao aktivatori topljive gvanilat ciklaze
WO2014047111A1 (en) 2012-09-18 2014-03-27 Ironwood Pharmaceuticals, Inc. Sgc stimulators
EP2897953B8 (en) 2012-09-19 2019-06-26 Cyclerion Therapeutics, Inc. Sgc stimulators
US9624214B2 (en) 2012-11-05 2017-04-18 Bayer Pharma Aktiengesellschaft Amino-substituted imidazo[1,2-a]pyridinecarboxamides and their use
EA027909B1 (ru) 2012-11-30 2017-09-29 Астеллас Фарма Инк. Имидазопиридиновые соединения
EA033168B1 (ru) 2013-03-15 2019-09-30 Сайклерион Терапьютикс, Инк. СТИМУЛЯТОРЫ sGC
WO2015033307A1 (en) 2013-09-05 2015-03-12 Glaxosmithkline Intellectual Property Development Limited Novel soluble guanylate cyclase activators and their use
CA2927420A1 (en) 2013-10-15 2015-04-23 Toa Eiyo Ltd. 4-aminomethylbenzoic acid derivative
WO2015088886A1 (en) 2013-12-11 2015-06-18 Merck Sharp & Dohme Corp. Soluble guanylate cyclase activators
WO2015088885A1 (en) 2013-12-11 2015-06-18 Merck Sharp & Dohme Corp. Soluble guanylate cyclase activators
CA2933250A1 (en) 2013-12-11 2015-06-18 Ironwood Pharmaceuticals, Inc. Sgc stimulators
US9796733B2 (en) 2014-06-04 2017-10-24 Merck Sharp & Dohme Corp. Imidazo-pyrazine derivatives useful as soluble guanylate cyclase activators
TW201625584A (zh) 2014-07-02 2016-07-16 諾華公司 茚滿及吲哚啉衍生物及其作為可溶性鳥苷酸環化酶活化劑之用途
TW201625601A (zh) 2014-07-02 2016-07-16 諾華公司 噻吩－２－基－吡啶－２－基－１ｈ－吡唑－４－羧酸衍生物及其作為可溶性鳥苷酸環化酶活化劑之用途
TW201625586A (zh) 2014-07-02 2016-07-16 諾華公司 環己烯－１－基－吡啶－２－基－１ｈ－吡唑－４－羧酸衍生物及其作為可溶性鳥苷酸環化酶活化劑之用途
PL3172202T3 (pl) 2014-07-22 2020-07-13 Boehringer Ingelheim International Gmbh Heterocykliczne kwasy karboksylowe jako aktywatory rozpuszczalnej cyklazy guanylanowej
US20170298055A1 (en) 2014-09-17 2017-10-19 Ironwood Pharmaceuticals, Inc. sGC STIMULATORS
EP3194382B1 (en) 2014-09-17 2021-09-08 Cyclerion Therapeutics, Inc. Pyrazole derivatives as sgc stimulators
EP3194386A2 (en) 2014-09-17 2017-07-26 Ironwood Pharmaceuticals, Inc. Sgc stimulators
PE20170937A1 (es) 2014-09-19 2017-07-13 Glaxosmithkline Ip Dev Ltd Nuevos activadores de la guanilato ciclasa soluble y su uso
TW201625635A (zh) 2014-11-21 2016-07-16 默沙東藥廠 作為可溶性鳥苷酸環化酶活化劑之三唑并吡基衍生物
WO2016191334A1 (en) 2015-05-27 2016-12-01 Merck Sharp & Dohme Corp. Imidazo-pyrazinyl derivatives useful as soluble guanylate cyclase activators
WO2016191335A1 (en) 2015-05-28 2016-12-01 Merck Sharp & Dohme Corp. Imidazo-pyrazinyl derivatives useful as soluble guanylate cyclase activators
JP6849618B2 (ja) * 2015-07-23 2021-03-24 バイエル・ファルマ・アクティエンゲゼルシャフト 中性エンドペプチダーゼの阻害剤（ＮＥＰ阻害剤）および／またはアンジオテンシンＩＩ拮抗薬と組み合わせた可溶性グアニル酸シクラーゼ（ｓＧＣ）の刺激薬および／または活性化薬ならびにその使用
CA3008776A1 (en) 2015-12-18 2017-06-22 Novartis Ag Indane derivatives and the use thereof as soluble guanylate cyclase activators
WO2017107052A1 (en) 2015-12-22 2017-06-29 Merck Sharp & Dohme Corp. Soluble guanylate cyclase stimulators
WO2017108441A1 (en) 2015-12-22 2017-06-29 Universiteit Maastricht Treatment of cognitive impairment with cgc stimulator
SI3507291T1 (sl) * 2016-09-02 2021-11-30 Cyclerion Therapeutics, Inc. Kondenzirani biciklični SGS stimulatorji
EP3525779B1 (de) * 2016-10-11 2024-06-05 Bayer Pharma Aktiengesellschaft Kombination enthaltend den sgc stimulator vericuguat und den mineralcorticoid-rezeptor-antagonist finerenone

Similar Documents

Publication Publication Date Title
JP2021522291A5 (enExample)
KR101517064B1 (ko) 3-(3-디메틸아미노-1-에틸-2-메틸-프로필)-페놀 및 ｎｓａｉｄ를 포함하는 약제학적 병용제
JP2020183410A5 (enExample)
US20080182845A1 (en) Method of preventing or treating organ, hematopoietic stem cell or bone marrow transplant rejection
JP2010515715A5 (enExample)
JP2009514874A5 (enExample)
JP2019505541A5 (enExample)
JP5667684B2 (ja) 関節炎の治療方法
JP2012532874A5 (enExample)
JP2008515905A5 (enExample)
EA032028B1 (ru) СТИМУЛЯТОРЫ рГЦ
JP2008509187A5 (enExample)
CN104220061A (zh) 含有富马酸二甲酯的药物组合物
JP2014139226A5 (enExample)
JP2012508734A5 (enExample)
JP2015506377A5 (enExample)
JP2017520613A5 (enExample)
TW200404531A (en) Synergistic combinations
JP2018511627A5 (enExample)
EP2664620A3 (en) N-((1R,2S,5R)-5-(tert-butylamino)-2-((S)-3-(7-tert-butylpyrazolo[1,5-A][1,3,5]triazin-4-ylamino)-2-oxopyrrolidin-1-yl)cyclohexyl)acetamide, a dual modulator of chemokine receptor activity, crystalline form and processes
US8735397B2 (en) Method for treating schizophrenia and related diseases
RU2019135261A (ru) Фармацевтическая композиция, содержащая ингибитор pde9
MX2021000904A (es) Forma de dosificacion farmaceutica administrable por via oral con liberacion modificada.
JP2009515951A5 (enExample)
JP2014527997A5 (enExample)